Company Overview and News

0
ESGR / Enstar Group Limited null

2018-07-11 sec.gov
begin 644 8A_Cert_Enstar.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected](# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T
ESGR

1
ESGR / Enstar Group Limited 8-A12B

2018-06-27 sec.gov
Document UNITED STATES
ESGR

1
ESGR / Enstar Group Limited 8-K (Current Report)

2018-06-27 sec.gov
Document UNITED STATES
ESGR

1
ESGR / Enstar Group Limited 8-K (Current Report)

2018-06-22 sec.gov
Document UNITED STATES
ESGR

13
エンスター・グループ・リミテッド、優先株の価格設定を発表

2018-06-21 globenewswire
バミューダ諸島ハミルトン, June 22, 2018 (GLOBE NEWSWIRE) -- エンスター・グループ・リミテッド (Enstar Group Limited) (NASDAQ:ESGR) は本日、16,000,000本の預託株式の公募価格を発表した。これらの各株は、シリーズD額面1.00ドル (約111円) の7.00%固定 / 浮動金利非累積永久優先株の1,000分の1の利権および1株当たり2万5,000ドル (約276万円) の残余財産分配に関する優先権 (預託株式1本あたり25ドル (約 2,760円) に相当) であり、総計公募価格は4億ドル (約442億円) に相当する。同公募は、通常のクローズ条件が充足されることを条件として、2018年6月27日にクローズになると予想されている。エンスターでは、クローズ後30日以内に預託株式をNASDAQグローバル・セレクト・マーケット (NASDAQ Global Select Market) でティッカーシンボル「ESGRP」として上場する予定である。
ESGR MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

13
Enstar Group Limited Announces Pricing of Preference Shares

2018-06-20 globenewswire
HAMILTON, Bermuda, June 20, 2018 (GLOBE NEWSWIRE) -- Enstar Group Limited (“Enstar”) (Nasdaq:ESGR) today announced the pricing of its public offering of 16,000,000 depositary shares, each representing a 1/1,000th interest in its 7.00% Fixed-to-Floating Rate Perpetual Non-Cumulative Preference Shares, Series D, $1.00 par value and $25,000 liquidation preference per share (equivalent to $25.00 per depositary share), for an aggregate public offering price of $400,000,000.
ESGR MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA

1
ESGR / Enstar Group Limited FWP

2018-06-20 sec.gov
Document PRICING TERM SHEET
ESGR

35
Enstar Group: Long-Term Compounder Focused On Run-Off Insurance And Opportunistic M&A

2018-06-20 seekingalpha
Enstar Group has managed a very impressive track record over time by being disciplined in acquiring blocks of insurance liabilities and executing strategic M&A.
BRK.A ESGR

1
ESGR / Enstar Group Limited 8-K (Current Report)

2018-06-18 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMI
ESGR

1
ESGR / Enstar Group Limited 424B2 (Prospectus)

2018-06-18 sec.gov
Document Filed Pursuant to Rule 424(b)(2)
ESGR

183
Tracking Charles Akre's Akre Capital Management Portfolio - Q1 2018 Update

2018-05-27 seekingalpha
The top three positions are American Tower, MasterCard, and Moody’s and they add up to ~38% of the entire portfolio.
ROP KKR KMX AMT.PRB BOMN AMT.PRA MCO CAXPF ALRM DLTR AMT VRSK AMTD UBNT MKL ESGR LAMR MA LKQ DHIL BRK.A PRMW V SBAC DHR ORLY

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

CUSIP: G3075P101